As I have mused about here before, clinical trial data on the use of resveratrol is all but absent, and what there is tends to show that it isn’t very well absorbed. So anyone bringing some clinical science to the field is to be congratulated. The study out this week actually measured blood flow to the brain during cognitive tasks, in other words things require thinking and concentration. Resveratrol improved blood flow and raised levels of the type of hemoglobin that has released its oxygen, implying higher oxygen extraction in the brain and therefore more processing power. The study was done in comparison to a placebo group, an important requirement for objectivity. The association of wine and IQ has long been known, whether it is due to smart people preferring wine or wine making people smart, so this study would add evidence to the latter explanation.
Not many people even thought about taking resveratrol supplements, however, until a few years ago when it was reported to activate enzymes known as sirtuins, which are involved in enhancing longevity. The biotech company Sirtris was founded to exploit this phenomenon, and was acquired by Glaxo a short time later. They soon developed several derivatives for treatment of cancer, diabetes, and other conditions, and clinical trials were launched on several fronts. This week a trial of resveratrol as an adjunctive treatment for a type of cancer called multiple myeloma was halted because of adverse safety events. However, the condition, a problem with the kidneys, is known to occur with the disease and seems unlikely to be related to the resveratrol. Nonetheless, it was a setback for those awaiting more potent versions of resveratrol to come to market.
For now, I’ll continue to take my medicine in liquid form, with dinner.